Clinical Evaluation Based on a New Approach to Improve the Accuracy of 4β-Hydroxycholesterol Measurement as a Biomarker of CYP3A4 Activity
Open Access
Abstract
This study examines 4β-Hydroxycholesterol (4β-HC), which is considered to be a potential marker for the CYP3A4 induction of new chemical entities (NCEs) in drug development. To ensure the use of 4β-HC as a practical biomarker, it is necessary to accurately measure 4β-HC and demonstrate that CYP3A4 induction can be appropriately assessed, even for weak inducers. In clinical trials of NCEs, plasma is often collected with various anticoagulants, in some cases, the plasma is acidified, then stored for an extended period. In this study, we examined the effects of these manipulations on the measurement of 4β-HC, and based on the results, we optimized the plasma collection and storage protocols. We also found that a cholesterol oxidation product is formed when plasma is stored, and by monitoring the compound, we were able to identify when plasma was stored inappropriately. After evaluating the above, clinical drug–drug interaction (DDI) studies were conducted using two NCEs (novel retinoid-related orphan receptor γ antagonists). The weak CYP3A4 induction by the NCEs (which were determined based on a slight decline in the systemic exposure of a probe substrate (midazolam)), was detected by the significant increase in 4β-HC levels (more specifically, 4β-HC/total cholesterol ratios). Our new approach, based on monitoring a cholesterol oxidation product to identify plasma that is stored inappropriately, allowed for the accurate measurement of 4β-HC, and thus, it enabled the evaluation of weak CYP3A4 inducers in clinical studies without using a probe substrate.Keywords
Funding Information
- Akros Pharma, Inc., Princeton, NJ, USA
This publication has 28 references indexed in Scilit:
- Stability: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization TeamThe AAPS Journal, 2014
- LC–ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volumeJournal of Pharmaceutical and Biomedical Analysis, 2013
- Comparison of Endogenous 4β-Hydroxycholesterol with Midazolam as Markers for CYP3A4 Induction by RifampicinDrug Metabolism and Disposition, 2013
- Quantification of 4-Beta-Hydroxycholesterol in Human Plasma Using Automated Sample Preparation and LC-ESI-MS/MS AnalysisChemical Research in Toxicology, 2011
- A validated liquid chromatography–tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2011
- 4β‐hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humansBritish Journal of Clinical Pharmacology, 2011
- Does the Long Plasma Half‐Life of 4β‐Hydroxycholesterol Impact Its Utility as a Cytochrome P450 3A (CYP3A) Metric?The Journal of Clinical Pharmacology, 2010
- Systematic LC‐MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well thought‐out chromatographyBiomedical Chromatography, 2009
- Metabolism of 4β-Hydroxycholesterol in HumansJournal of Biological Chemistry, 2002
- INHIBITION OF DNA-DEPENDENT RNA SYNTHESIS BY RIFAMYCINSThe Journal of Antibiotics, 1968